Kornimate/medical-research-clean huggingface dataset:
prospective observational study on comprehensive effects of peek cranioplasty and titanium cranioplasty after dc（recept-dc）

Conditions: Skull Defect

Summary: the objective of this trial is to scientifically evaluate the efficacy of peek cranioplasty and titanium cranioplasty. the primary objective is to compare the rate of implant failure (defined as infection, implant exposure and other causes requiring removal of the implanted material) at any time within 12 months after cranioplasty. the secondary objective is to compare the complication rates and neurological function recover following cranioplasty. complication events after cranioplasty are investigated within 6 months after surgery and neurological function is evaluated at 3, 6 and 12 months after cranioplasty.


Eligibility criteria:
inclusion criteria: * skull defect with a diameter greater than 3cm * no intracranial hemorrhage, intracranial hypertension or hydrocephalus (or treated) occurred more than 1 month after the previous operation * cranioplasty is feasible according to doctor's evaluation * patients must agree to participate in this clinical trial and the informed consent is signed by patients themselves or next of kin on behalf of the patient. exclusion criteria: * manifestations of intracranial hypertension or untreated hydrocephalus * poor healing of skin wound * intracerebral infection or intracerebral hematoma is not cured * patients with operational contradictions, for example, poor general condition

Keywords: skull defect epilepsy infections
dual-task performance in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: multiple sclerosis (ms) is a chronic inflammatory disease affecting the central nervous system. it is reported that 85% of patients with multiple sclerosis have gait disturbance, 88% balance, and 35-90% fatigue (1, 2, 3). in addition, 65% of patients are reported that their cognitive functions have regressed (4). it is important to increase the independence of the ms patients in activities of daily living (adl). almost all of adl requires many activities at the same time. for example, toothbrushing involves both the standing balance and the motor activity of the upper limb at the same time. it also requires cognitive tasks such as attention and focusing. many activities that seem to be the only task are actually multitasking (5). the aim of this study is to investigate the effects of motor and cognitive additional task on balance, mobility and upper limb performances in ms patients and to determine the factors associated with dual-task performance.

patients with ms between 0-5,5 score according to the extended disability status scale (edss) and healthy individuals of similar age and sex to patients will be included in the study. the balance, mobility, upper extremity performance, cognitive function, fatigue, physical activity level, mood, sleep quality, quality of life will be evaluated once. we will use descriptive statistics and t-tests to compare demographic characteristics between groups and for the categorical variables chi-square. effect of the group (ms patients or healthy controls), condition (single task and dual-task conditions), and group × condition interaction will be compared using two-way repeated measures anova. we will examine the correlations between fatigue severity, physical activity level, mood, sleep quality, quality of life using pearson bivariate correlations. the significance level is set at p\<0,05.

Eligibility criteria:
inclusion criteria: * participants who 18-65 years of age * ms patients who are ambulatory (expanded disability status scale score ≤ 5,5 ) in a stable phase of the disease, without relapses in the last 3 month. exclusion criteria: * participants who have orthopedic, vision, hearing, or perception problems

Keywords: multiple sclerosis dual-task balance mobility cognition
anti-cancer neoantigen mrna vaccine to treat solid tumors

Conditions: Solid Tumor, Adult

Summary: the wes and ran-seq will be performed to identify and verify neoantigens and appropriate mrna sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. clinical studies will be performed to test anti-cancer function of the mrna vaccine for immunotherapy of human cancer patients. in this phase i study, the safety, tolerance, and preliminary efficacy of the mrna vaccine immunotherapy on human cancers will firstly be evaluated.

1. choose appropriate patients with advanced solid cancers, with written consent for this study; 2. perform biopsy to get fresh sample for dna/rna-seqencings and bioinformatics analysis; 3. produce high quality mrna vaccine and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required; 4. to enhance the killing capability, cotreatment the patients with pd1/pdl1/ctla4 antibodies may be applied; 5. evaluate the clinical results as needed.

Eligibility criteria:
inclusion criteria: 1. patients with advanced cancer; 2. life expectancy \>12 weeks; 3. adequate heart, lung, liver, kidney, and blood function; 4. available high quality vaccine for human use; 5. informed consent explained to, understood by and signed by patient/guardian. patient/guardian given copy of informed consent. - exclusion criteria: 1. had accepted gene therapy before; 2. severe virus infection such as hbv, hcv, hiv, et al; 3. known hiv positivity; 4. active infectious disease related to bacteria, virus,fungi,et al; 5. other severe diseases that the investigators consider not appropriate; 6. pregnant or lactating women; 7. systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); 8. other conditions that the investigators consider not appropriate.

Keywords: mrna vaccine solid tumor immunotherapy
low carb diets & exercise for cardiovascular disease (cvd) reduction

Conditions: Obesity

Summary: the purposes of this study are: to investigate the effects of a 6 month low carbohydrate diet in obese men on markers of heart health including blood fats, blood clotting factors, inflammatory markers and levels of body fat. to investigate the added effect on heart health that regular moderate exercise may have when combined with a low carbohydrate diet in obese men.


Eligibility criteria:
inclusion criteria: * male * 21-65 years * body mass index (bmi) 27-40kg/m2 * not currently losing weight * physically able to exercise at moderate intensity

Keywords: low carbohydrate diet obesity moderate exercise men
computed tomography arteriograms (cta) volume dose reduction study

Conditions: Aortic Aneurysm; Contrast Induced Nephropathy; Aortic and Arterial Anomalies

Summary: the purpose of the study is to determine if the dose of contrast (omnipaque) administered for computed tomography arteriograms (cta) can be reduced without degradation of image quality. the hypothesis is that there is no difference in image quality using ultra-low dose contrast in cta exams compared to routine, standard of care dose exams.

any adult patient age 18 and above, scheduled for routine cta (computed tomography arteriograms) of the chest or chest, abdomen and pelvis meeting inclusion criteria and not meeting any exclusion criteria will be included in the study. the patient will be administered a low dose of intravenous contrast based on the study examination as described below. cta of the chest: 40 ml of intravenous contrast (omnipaque) at a rate of 5ml/sec. a region of interest (roi) to trigger the scan will be placed in the aortic arch. if scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. cta of the chest and abdomen or cta of the chest, abdomen and pelvis: 50 ml of intravenous contrast (omnipaque) at a rate 5ml/sec. a region of interest (roi) to trigger the scan will be placed in the aortic arch. if scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. following the examination, the primary investigator (pi) or team members will evaluate the images obtained with low contrast dose and each patient's prior cta examination performed with routine contrast dose, 100ml at a rate of 4ml/sec. this will be done by quantitative and qualitative measures. for the quantitative portion, the pi or team members will place regions of interest on predetermined arterial locations to obtain measure the degree of opacification. for qualitative measurement, the images will be presented in a blind fashion to two thoracic trained board certified radiologists and a board certified interventional radiologist to determine the quality of the images based on a likert numerical scale. qualitative and quantitative data for the images obtained with low contrast dose and those for the prior cta examinations performed with routine contrast dose will be compared. this data along with details of the scan protocol (dose, dose rate, scanning parameters etc.) and demographic data (such as sex, age and bmi at the time of examination) will be recorded.

Eligibility criteria:
inclusion criteria: * any adult patient scheduled for a computed tomographic arteriogram (cta) of the chest or chest, abdomen and pelvis who had undergone a prior cta performed with the standard contrast dose (100 ml) at this institution will be included in the study * the follow-up scan will be routine standard of care, no emergency imaging patient will be approached for this research exclusion criteria: * patients with no prior cta imaging for comparison * any pediatric patient (age \<18) * bmi \>40 * inability to follow instructions * allergy to intravenous contrast * gfr less than 30 ml/min/1.73 m2
a comparative study of the tolerability of two combination therapies for the treatment of acne

Conditions: Acne Vulgaris

Summary: the purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.

the purpose of this study is to compare the tolerability of topical combination therapies in the treatment of facial acne.

Eligibility criteria:
inclusion criteria: * male or female subjects at least 21 years of age, in good general health with documented diagnosis of acne vulgaris. * female subjects of childbearing potential must have a negative pregnancy test. sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception abstinence is considered an acceptable method of contraception. * inflammatory (papules and pustules) and non-inflammatory (open and closed comedones) facial lesions. * the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study * capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol specific procedures are performed exclusion criteria: * female subjects who are pregnant, trying to become pregnant or breastfeeding. * subjects who have any clinically relevant finding at their baseline physical other than acne vulgaris. * history or presence of regional enteritis or inflammatory bowel disease (eg, ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of antibiotic-associated colitis) or similar symptoms. * use of topical antibiotics or anti-acne medications on the face and systemic antibiotics within the past 2 and 4 weeks, respectively. * use of topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. use of inhaled, intra-articular or intra-lesional (other than for facial acne lesions) steroids is acceptable. * use of systemic retinoids within the past 6 months. * facial procedures performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or during the conduct of the study. * known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, adapalene, clindamycin, benzoyl peroxide or excipients of the study product.

Keywords: acne acne vulgaris
gastroduodenal intussusception: two cases of gastroduodenal intussusception following gastric plication, each managed with a different approach.

Conditions: Bariatric Surgery; Intussusception

Summary: the investigators received two female patients in the hospital who developed gastroduodenal intussusception following gastric plication procedure, requiring surgical treatment. both patients presented with non-specific, atypical abdominal pain several months after the gastric plication. both patients required surgical intervention, which included manual reduction of the plication followed by subtotal gastrectomy en bloc with roux-en-y reconstruction. in the second case, an omega brown anastomosis was performed, and a jejunostomy was created after the anastomosis in both patients.


Eligibility criteria:
inclusion criteria: - patients with gastro-duodenal intussusception following a gastric plication procedure. exclusion criteria: * children

Keywords: case report gastric plication
amotosalen and platelet transfusion in pediatric heart surgery

Conditions: Congenital Heart Disease in Children

Summary: high level of security during blood transfusion has been achieved by donor selection and pathogen detection using serology or direct identification. nevertheless, blood banking becomes hazardous during epidemic outbreaks or facing new pathogens. amotosalen, a psoralen, targets nucleic acids and destroys them after ultraviolet exposure, resulting in inactivation of pathogens. treatment inoccuity and efficacy have been demonstrated but preservation of platelet functions after treatment is still debated. previous studies focused on hematological patients. there is no evidence for an increased requirement of transfused platelets to achieve platelet count target. studies in heart surgery are lacking. the investigators perform a multicenter, retrospective, "before/after", controlled study in minor patients requiring heart surgery with cardiopulmonary bypass. one center (strasbourg) uses amotosalen-treated platelet concentrates since 2006 (control arm). this treatment becomes available in bordeaux in october 2017 (intervention arm). there is two periods of inclusion: one "before" (january 2016 to june 2017) and one "after" (january 2018 to june 2019).


Eligibility criteria:
inclusion criteria: * minor patient (\<18 years old) * cardiac surgery act under cardiopulmonary bypass for correction of congenital heart disease * platelet transfusion for any reason * cardiac surgery performed at bordeaux or strasbourg university hospital over two periods: * period a: january 01, 2016 - june 30, 2017 (before treatment) * period b: january 01, 2018 - june 30, 2019 (after treatment) * subject (and / or his parental authority) not having expressed, after information, his opposition to the reuse of his data for the purposes of this research exclusion criteria * subject (and / or his parental authority) having expressed, after information, his opposition to the reuse of his data for the purposes of this research * presence or installation of transient circulatory assistance (outside of the cec) or definitive * heart or cardiopulmonary transplantation

Keywords: congenital heart platelet transfusion procoagulant drugs amotosalen pediatric heart surgery
circulating tumor dna as marker of therapeutic efficacy in breast cancer patients

Conditions: Breast Neoplasms

Summary: in nonmetastatic local advanced breast cancer patients, we are going to investigate whether circulating tumor dna (ctdna) detection can reflect the tumor response to neoadjuvant chemotherapy (nct) and detect minimal residual disease after surgery.

breast cancer is the most common malignant tumor in women worldwide, and chemotherapy is still the main method of breast cancer treatment. and for locally advanced breast cancer patients, neoadjuvant chemotherapy can further improve treatment efficacy, improve prognosis and increase the rate of breast conserving surgery. the persistence of a minimal residual disease at distant sites after the treatment of a localized breast cancer is a key parameter for posttreatment survival but cannot be reliably assessed by the current biological or radiological tools. therefore, the prediction of the chemotherapy efficacy is very important. ctdna, corresponds to fragmented dna released into the blood stream by tumor masses, the detection and quantification of circulating tumor dna (ctdna) is a very promising tool that can assess tumor burden, response to therapy, and minimal residual disease. in this study, we wil collect breast cancer cases treated with neoadjuvant chemotherapy, draw blood and evaluate the efficacy each time before chemotherapy and after surgery, then measure the concentration of ctdna in each sample. we will also analyze the demographic data,basic treatment and follow-up data including relapse, metastasis and survival.

Eligibility criteria:
inclusion criteria: * patients pre- or post-menopausal must have histologically confirmed early stage/locally advanced invasive breast cancer; * tumor size ≥ 0.5cm (clinical or radiographic measurements); * any nodal status allowed; * age \> 18 years old; * felt to be a possible candidate for neoadjuvant systemic therapy by their treating physician; * ecog score\<=2; exclusion criteria: * known metastatic disease; * with serious heart, lung, liver diseases; * poor cardiac function; * pregnant; * patients with other malignant tumor or treated before;

Keywords: ctdna
a study of merestinib (ly2801653) in japanese participants with advanced or metastatic cancer

Conditions: Advanced Cancer; Metastatic Cancer; Biliary Tract Carcinoma; Cholangiocarcinoma; Gall Bladder Carcinoma; Solid Tumor; Non-Hodgkin's Lymphoma

Summary: the main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in japanese participants with advanced and/or metastatic cancer.


Eligibility criteria:
inclusion criteria: * part a: histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic (solid tumors or non-hodgkin's lymphoma). * part b: biliary tract carcinoma that is unresectable, recurrent, or metastatic. the participant must not have received prior systemic front-line therapy for metastatic or resectable disease. * part a: measurable or nonmeasurable disease as defined by response evaluation criteria in solid tumors (recist) v1.1 or cheson criteria. * part b: measurable disease as defined by recist v1.1. * adequate organ function including hematologic, hepatic and renal. * eastern cooperative oncology group (ecog) scale of 0 or 1. * are able to swallow tablets. * for participants in part b, a tumor tissue sample is mandatory for biomarker analysis. * males must agree to use medically approved barrier contraceptive precautions during the study and for 3 months following the last dose of study drug. * females with childbearing potential: must agree to use medically approved contraceptive precautions during the study and for 3 months following the last dose of study drug, must have had a negative serum or urine pregnancy test ≤7 days before the first dose of study drug. * a breastfeeding woman must not be breastfeeding. if a female who stops breastfeeding enters the study, breastfeeding must cease from the day of the first study drug administration until at least 3 months after the last administration. exclusion criteria: * have serious pre-existing medical conditions. * have a chronic underlying infection. * have symptomatic central nervous system malignancy or metastasis. * have an active fungal, bacterial, and/or known viral infection. * part b: have mixed hepatocellular biliary tract carcinoma histology. * have liver cirrhosis with a child-pugh stage of b or higher, or have received a liver transplant. * have a history of congestive heart failure with new york heart association (nyha) class greater than 2, unstable angina, or have recent history of myocardial infarction, transient ischemic attacks, stroke, or arterial or venous vascular disease. * have a corrected qt interval \>470 milliseconds as calculated be the fredericia equation. * have a second primary malignancy that, in the judgment of the investigator, and sponsor may affect the interpretation of results. * have any evidence of clinically active interstitial lung disease (ild).

Keywords: neoplasm
the effect of adjunct vitamin a on community-acquired pneumonia in southern iranian children: a randomized clinical trial

Conditions: Community-Acquired Pneumonia; Vitamin a

Summary: this randomized clinical trial included 105 children with cap who were admitted to bandar abbas children's hospital. participants were randomly assigned to two groups: a control group receiving standard antibiotic therapy and an intervention group receiving standard antibiotics plus vitamin a (25,000 iu for 2 days). key data collected included age, sex, duration of hospitalization, treatment duration, and daily respiratory index of severity in children (risc) scores.

children to present with cap symptoms

Eligibility criteria:
inclusion criteria: * children to present with cap symptoms, including fever, cough, pulmonary rales, respiratory distress (age-adjusted tachypnea: \>50 breaths per minute for infants under 1 year, \>40 for ages 1-5 years, and \>30 for those over 5 years), and radiographic findings indicative of pneumonia. exclusion criteria: * underlying immunodeficiency, chronic respiratory conditions, concurrent use of immunosuppressive medications, prior high-dose vitamin a intake, and hospitalizations shorter than 24 hours

Keywords: community-acquired pneumonia vitamin a pediatrics hospitalization southern iran